Alizyme Share Discussion Threads

[the_doctor] 08/7/2009 06:46

Someone may buy them, yes.... because it is a cheaper way of running it.
Just stick the ceti assets and maybe a couple of staff in with another company.

But dont expect anything decent if it happens.

Vernalis may be happy to take ATL104? As for ceti, I doubt they'd want it, but might be happy to sit with the rights.

[silverbackalpha] 07/7/2009 22:52

negotiations are progressing is a meaningless statement as far as Tim is concerned.

[vow] 07/7/2009 22:33

I have asked Tim this about FDA requirements and the answer is no. Completely fresh trials would need to be done for each regulatory body.

[city chappy] 07/7/2009 22:26

troutfish you could be on to something. The Takeda data for Phase 3 Cetilistat Japan might satisfy regulatory requirements for several South-east Asian countries with similar ethnic types to Japan therefore reducing or eliminating the need for trials in those territories and making a deal or deals more attractive.

Does anyone know if any of these territories accept data from Japanese trials run by quality companies like Takeda are doing with Cetilistat in Japan? I suspect some do.

South Korea
China, Hong Kong, Taiwan
Vietnam
Thailand
Malaya
Singapore
Philippines

Any others?

[the_doctor] 07/7/2009 18:19

Well, you're still in the same stinking frying pan really I'm afraid

[dunderheed] 07/7/2009 18:10

Yep that's what worries me!
Out of the frying pan and into the fire comes to mind!!

[loafofbread] 07/7/2009 18:05

Have to agree with that.

[gambill] 07/7/2009 15:07

Well Silver if you dont owe shares why bother.

[troutfish] 07/7/2009 15:01

It occurrs to me that AZM's statement on 19/5/2009: "Negotiations are progressing with potential patners to license Cetilistat for territories outside Japan", could include territories other than North America or Europe, such as other parts of the middle and far east.

In addition I wonder if such other territories might require less costly trials, and/or could use some of the Takeda data to date and/or expected next year, in order to put Cetilistat on the market in those other territories without the level of costs associated with further development for North America and Europe.

[silverbackalpha] 07/7/2009 14:13

Still isn't enough IMO;



Filbert3 - 7 Jul'09 - 12:52 - 23937 of 23937


Goodman is also not whiter than white re his activities at CeNes.

They clearly mis-represented the Phase 3 results when they were announced - saying in the headline the trial was a success when in actual fact if you read deep into the annoucement it was clear it had failed, and he also over -promoted the M6G prospects re partners in much the same way McCarthy seems to have here. Peas out of much the same pod, in my view.

[chronicler] 07/7/2009 13:31

hilarious.....

[vow] 07/7/2009 13:15

Qaz,

We all know you are the worst investor on ADVFN. You must have called AZM, CEN and OXB wrong at least 10 times each.

Stubborn Germanic trait eh?

[chronicler] 07/7/2009 13:05

vow in other words you are an even bigger loser than we already thought.

[filbert3] 07/7/2009 12:52

Goodman is also not whiter than white re his activities at CeNes.

They clearly mis-represented the Phase 3 results when they were announced - saying in the headline the trial was a success when in actual fact if you read deep into the annoucement it was clear it had failed, and he also over -promoted the M6G prospects re partners in much the same way McCarthy seems to have here. Peas out of much the same pod, in my view.

[vow] 07/7/2009 12:45

Paion is listed in Germany, a LOT cheaper and easier to trade than the Canadian exchange.

Most boiler rooms operate out of Canada as the regulation there is awful. It is not a crime to rip off anyone outside Canada while on Canadian soil.

So as soon as I heard their plan to go over there I bailed for the couple of pence a share I had left!

[johndee] 07/7/2009 12:44

the market seems to indicate this is not over by any means and hope is still there.

[dunderheed] 07/7/2009 12:34

Oh right could not remember if cenes or paion or whatever - was Canadian listed or German?

[vow] 07/7/2009 12:33

Nope.

Had a VERY similar experience with CeNeS. Took part in a couple of placings on the back of the drug that shall not be mentioned and then sold out a couple of months before the were taken out, although this seems to be moving a lot quicker.

[dunderheed] 07/7/2009 12:19

Was that cenes?

[silverbackalpha] 07/7/2009 12:14

More on AG and Tim:



Alizyme founder steps down as Goodman takes the reins
Written by News Desk
Monday, 06 July 2009

Tim McCarthy has stepped down as CEO of struggling Cambridge biotech Alizyme, with Chiroscience, Acambis and CeNeS founder Alan Goodman stepping in on an interim basis.

According to a statement from the company, Goodman - who was appointed a director in late April - will be taking charge of the day to day affairs of the company during what is described as a "period of reconstruction." Alizyme announced in June that it faces bankruptcy if it doesn't secure fresh funding by the end of August.

McCarthy co-founded Alizyme in 1995, serving as finance director until 2006 when he replaced Dr Richard Palmer as CEO.

As chief executive of biotech venture capital firm, Avlar Bioventures, Goodman's turnaround skills are in demand elsewhere within its portfolio. York Pharma is fighting to find funding to repay a line of credit before July 22 and meet its working capital requirements; while Intercytex is undertaking a cost cutting exercise - including redundancies.

The future of Cambridge biopharma development company remains in the balance despite a promising looking update on its product pipeline.

The share price had dipped almost 12 per cent to 6p following the update.

The company had cash of £2.2 million at December 31 topped up in Q1 2009 by an R & D tax credit of £1.4 million.

Internal overhead costs have been substantially cut, as has external R & D spend. And to ensure overall board remuneration was in line with the generally reduced costs going forward, in March the directors waived a third of their future entitlement to remuneration and fees, with effect from April 1. Headcount reduced from 13 to 11.

An interim management statement reported: "There remains a material uncertainty over the company's ability to continue as a going concern." Alizyme's Cetilistat, for obesity and type 2 diabetes, is continuing through its Phase III clinical development in Japan with partner Takeda Pharmaceutical. Cetilistat has successfully completed an extensive Phase I and Phase II clinical develop ment programme and been prepared for the start of Phase III development outside Japan. Negotiations are progressing with potential partners to license cetilistat for territories elsewhere.

Norgine BV, Alizyme's partner for the ulcerative colitis treatment, COLALPRED in Europe, South Africa and Australasia, is progressing further development and submission of a Marketing Authorisation Application for the EU.

Prometheus Laboratories Inc is progressing a Phase II study in the US, while TSD Japan Inc, is advancing a Phase I study in Japan.

With its ATL-104 for treating mucositis, Alizyme says that having successfully completed a Phase IIa 'proof of concept' clinical trial in patients with lymphoma and myeloma the preparation for a further Phase I study – this time in head and neck cancer – and the transfer of the recombinant protein to a large scale manufacturer in advance of Phase II development and potential comm ercial supply will continue when financial resources permit.

[ant15] 07/7/2009 12:12

Like I said previously VOW Funding for BIOTECH is difficult to raise and when its all you have been doing for 25 years as in his case others will court favours and advice.On a brighter not What a change to see AZM third on the highest gainers board today...thats not happened since I dont recall.

[vow] 07/7/2009 11:59

Didn't know this: So where is AZM in the queue?

Monday, 06 July 2009

"As chief executive of biotech venture capital firm, Avlar Bioventures, Goodman's turnaround skills are in demand elsewhere within its portfolio. York Pharma is fighting to find funding to repay a line of credit before July 22 and meet its working capital requirements; while Intercytex is undertaking a cost cutting exercise - including redundancies. "